Determination of Genotypes in Cytomegalovirus (CMV) Strains Obtained from Pediatric and Adult Immunocompromised Patients

Yıl 2023, Cilt: 7 Sayı: 1, 270 - 276, 31.01.2023

Ayşenur Coşkun , Selma Gökahmetoğlu , Pelin Özmen , Şerife Çevik , Musa Karakükcü , Leylagül Kaynar , Kenan Midilli , Mert Kuskucu

https://doi.org/10.30621/jbachs.1095228

Cited By: 1

Öz

Background and Purpose: Cytomegalovirus causes asymptomatic disease in individuals with normal immune system; and leads to serious complications in immunocompromised individuals and fetus. In CMV, gB is the most studied glycoprotein in terms of genotyping. Up to now, four different gB genotypes (gB 1-4) of CMV have been identified.
In this study, it was aimed to determine the genotypes of CMV strains obtained from patients with immune deficiency.
Methods: Twenty children and 29 adults, 49 patients who were followed in the Department of Adult Hematology and Pediatric Hematology were included in the study. DNA isolation was performed from samples with CMV DNA level of 1000 IU / ml and above, and 474 bp region from the gB region of the virus was amplified by nested PCR. This region was sequenced by the Sanger (ABI 3500 Prism) sequencing. Next generation sequencing (NGS) method was applied to the samples that CMV genotype could not be determined by Sanger sequencing.
Results: Distribution of CMV genotypes of patients determined by Sanger sequencing; while it was determined as 18/49 (36.7%) type 1, 5/49 (10.2%) type 2, 5/49 (10.2%) type 3 and 1/49 (2%) type 4; 14/49 (28.5%) of them were found as mixed genotypes. CMV genotype could not be determined in 6 patients by Sanger sequencing and CMV genotype of these 6 patients were found as mixed genoype by NGS. Mixed genotype was detected in 20 (40.9%) of 49 patients, in total by Sanger sequencing and NGS.
Conclusion: It is remarkable that the most common genotype is mixed genotype. It was concluded that it is appropriate to study the next generation sequencing method in patients whose CMV genotype cannot be determined by Sanger sequencing.

Anahtar Kelimeler

Cytomegalovirus, genotype, sequencing, NGS

Proje Numarası

TYL-2017-7428

Kaynakça

• Referans 1. Çolak D. Zarflı DNA Virüsleri. In: Şener B, Esen B, editors. Basic Microbiology and İmmunology. 14 th ed . Ankara: Güneş Med Press ;2017. p. 295-96
• Referans 2. Goodwin ML, Webster HS, Wang HY, et al. Specificity and effector functions of non-neutralizing gB-specific monoclonal antibodies isolated from healthy individuals with human cytomegalovirus infection. Virology 2020;548: 182–191.
• Referans 3. Dağlar DE, Öngüt G, Çolak D,et al. Determination of Cytomegalovirus Glycoprotein B Genotypes in Different Geographical Regions and Different Patient Groups in Turkey. Mikrobiyol Bul 2016; 50: 53-62.
• Referans 4. Ciotti M, Cella E, Rittà M, et al. Cytomegalovirus Glycoprotein B Genotype Distribution in Italian Transplant Patients. Intervirology 2017;60:4, 165–170.
• Referans 5. Sarkar A, Das D, Ansari S, et al. Genotypes of glycoprotein B gene among the Indian symptomatic neonates with congenital CMV infection. BMC pediatrics 2019;19: 291.
• Referans 6. Janković M, Ćupić M, Knežević A, et al. Cytomegalovirus glycoprotein B and N genotypes in pediatric recipients of the hematopoietic stem cell transplant. Virology 2020; 548: 168–173.
• Referans 7. Hodinka RL. Human Cytomegalovirus, In: Jorgensen JH, Pfaller MA, Carrol KC, Landry ML, Funke D, Richter SS, (Eds), Manual of Clinical Microbiology ,11th ed, Vol 2, ASM Press, Washington DC: 2016. p.1718-36.
• Referans 8. Ross SA, Pati P, Jensen TL,et al. Cytomegalovirus Genetic Diversity Following Primary Infection. Journal of Infectious Diseases 2020;221: 715–720.
• Referans 9. Chou S. Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance. Antiviral research 2020;176:104711.
• Referans 10. Roubalova K, Strunecky O, Zufanova S, Prochazka B, Vitek A. Genotyping of viral glycoprotein B (gB) in haemopoetic stem cell transplant recipients with active cytomegalovirus infection : analysis of the impact of gB genotypes on the patients' outcome. Epidemiol Microbiol İmmunol 2010; 59: 92-99.
• Referans 11. Torok-Storb B, Boeckh M, Hoy C. Association of specific cytomegalovirus genotypes with death from myelosupression after marrow transplantation. Blood 1997; 90: 2097-2102.
• Referans 12. Woo PC, Lo CY, Lo SK. Distinct genotypes distributions of cytomegalovirus (CMV) envelope glycoprotein in bone marrow and renal transplant recipients with CMV disease. Clinical and Diagnostic Laboratory İmmunology 1997;4: 515-518.
• Referans 13. Manuel O, Husain S, Kumar D, et al. Assesment of cytomegalovirus- spesific cell-mediated immunity for the predicition of cytomegalovirus disease in high risk solid organ transplant recipients: a multicenter cohort study. Clin Infect Dis 2013; 56: 817-824.
• Referans 14. Soleimani AR, Jafari M, Piroozmand A, Nikoueinejad H., Akbari H, Einollahi B. The Incidence of Cytomegalovirus Glycoprotein B Genotypes in Kidney Transplant Recipients in Iran. Int J Org Transplant Med 2018; 9:4.
• Referans 15. Barrado L, Prieto C, Hernando S, Folgueira L. Detection of glycoproteins B and H genotypes to predict the development of Cytomegalovirus disease in solid organ transplant recipients. Journal of Clinical Virology 2018; S1386-6532(18)30278-6.
• Referans 16. Parkan ÖM, Görzer I, Çolak D, Sarıtaş ZE, Sağlık İ, Sarınoğlu RC, et al. Investigation of CMV Genotypes in Cases With Congenital Cytomegalovirus (CMV) Infection. 5th National Clinical Microbiology Congress Book, İzmir, 2019. S11-189.
• Referans 17. Kılınç A, Gökahmetoğlu S. Investigation of Genotypes of Cytomegalovirus (CMV) Strains Isolated from Clinical Specimens, 4th National Virology Congress Proceedings with International Participation, 2011, İstanbul. S. 150
• Referans 18. Vinuesa V, Bracho MA, Albert E, et al. The impact of virus population diversity on the dynamics of Cytomegalovirus DNAemia in allogeneic stem cell transplant recipients. Journal of General Virology 2017;98:2530–2542.
• Referans 19. Coaquette A, Bourgeois A, Dirand C, et al. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clinical İnfectious Diseases 2004; 39: 155-161.
• Referans 20. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resistance Updates 2002; 5: 88-114.
• Referans 21. Arav RB. Strain Variation and disease severity in congenital CMV infection – in search of a viral marker. Infect Dis Clin North Am 2015 ; 29 401–414.